Table 1.
Patient, disease, and transplantation characteristics by recipient age at transplantation
| Variable | Aged 20 y or younger* |
Older than 20 y† |
||
|---|---|---|---|---|
| Bone marrow | Peripheral blood | Bone marrow | Peripheral blood | |
| No. | 305 | 44 | 253 | 90 |
| Male sex, no. (%) | 185 (61) | 24 (55) | 148 (59) | 44 (49) |
| Performance score, no. (%) | ||||
| 90-100 | 180 (59) | 25 (57) | 110 (43) | 32 (36) |
| Lower than 90 | 81 (27) | 13 (30) | 94 (37) | 43 (48) |
| Unknown | 44 (14) | 6 (14) | 49 (19) | 15 (17) |
| Interval, diagnosis to HCT, no. (%) | ||||
| ≤ 6 mo | 248 (81) | 33 (75) | 167 (66) | 46 (51) |
| Longer than 6 mo | 57 (19) | 11 (25) | 86 (34) | 44 (49) |
| Years of transplantation, no. (%) | ||||
| 1995-1999 | 201 (66) | 18 (41) | 175 (69) | 33 (36) |
| 2000-2003 | 104 (34) | 26 (59) | 78 (31) | 57 (64) |
| Conditioning regimen, no. (%) | ||||
| TBI + other | 19 (6) | 2 (5) | 12 (5) | 7 (8) |
| Cy + TLI/TAI ± ATG | 11 (4) | 2 (5) | 22 (9) | 6 (7) |
| Cy + ATG | 193 (63) | 21 (48) | 118 (47) | 44 (49) |
| Cy | 62 (20) | 13 (30) | 67 (26) | 11 (12) |
| Bu + Cy ± other | 16 (5) | — | 22 (9) | 4 (4) |
| Fludarabine + other | 2 (1) | 6 (14) | 9 (4) | 16 (18) |
| Cy + thiotepa | — | — | 2 (<1) | 1 (1) |
| Unknown | 2 (1) | — | 1 (<1) | 1 (1) |
| GVHD prophylaxis, no. (%) | ||||
| None | 1 (<1) | — | 2 (1) | — |
| CSA ± other | 38 (13) | 12 (27) | 33 (13) | 24 (27) |
| CSA + MTX ± other | 255 (84) | 28 (64) | 214 (85) | 51 (57) |
| Tacrolimus ± other | 2 (1) | — | 1 (<1) | 6 (7) |
| Other | — | 2 (5) | ||
| Unknown | 9 (3) | 2 (3) | 3 (1) | 9 (10) |
| Donor-recipient sex match, no. (%) | ||||
| Male to male | 90 (30) | 9 (20) | 93 (37) | 20 (22) |
| Male to female | 66 (22) | 9 (20) | 63 (25) | 28 (31) |
| Female to male | 95 (31) | 14 (32) | 55 (22) | 24 (27) |
| Female to female | 54 (18) | 12 (27) | 41 (16) | 18 (20) |
| Unknown | — | — | 1 (<1) | — |
| Follow-up of survivors, median (range), mo | 68 (16-131) | 50 (22-105) | 68 (13-134) | 41 (15-102) |
A total of 155 transplantation centers contributed data for this study. Of these, 91 transplantation centers contributed data on BM transplantations only, 27 centers contributed data on PBPC transplantations only, and 37 centers contributed data on both BM and PBPC transplantations. Most transplantation centers (121 [78%] of 155) contributed 5 or fewer patients, 22 (14%) centers contributed 6 to 10 patients, and only 12 (7%) centers contributed more than 10 patients. The median number of patients per center is 3.
HCT indicates hematopoietic stem cell transplantation; TBI, total body irradiation; TLI, total lymphoid irradiation; TAI, total abdominal irradiation; Cy, cyclophosphamide; ATG, antithymocyte globulin; Bu, busulfan; CSA, cyclosporine; and MTX, methotrexate; — indicates not applicable.
A total of 107 centers performed transplantations on patients 20 years old and younger. A total of 91 (85%) centers performed transplantations on 5 or fewer patients, 13 (12%) centers performed transplantations on 6 to 10 patients, and 2 (3%) centers performed transplantations on more than 10 patients. The median number of patients who received transplants per center is 2.
A total of 109 centers performed transplantations on patients older than 20 years. A total of 94 (86%) centers performed transplantations on 5 or fewer patients, 9 (8%) centers performed transplantations on 6 to 10 patients, and 6 (6%) centers performed transplantations on more than 10 patients. The median number of patients who received transplants per center is 2.